Aktie A3C4Y0 ABBISKO CAYMAN LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Abbisko Cayman Limited

Aktien

A3C4Y0

KYG0028A1085

2256

Markt geschlossen - Hong Kong S.E.
Andere Börsenplätze
 10:08:20 26.04.2024 		% 5 Tage % 1. Jan.
3.28 HKD +4.79% Intraday Chart für Abbisko Cayman Limited +13.10% -10.14%
25.04. Leberkrebsmedikament von Abbisko Cayman erhält US FDA Orphan Drug Designation MT
24.04. Abbisko Cayman Limited kündigt Rücktritt von Tian Huimin als Joint Company Secretary an CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Abbisko Cayman's Liver Cancer Drug Gets US FDA Orphan Drug Designation
Abbisko Cayman Limited Announces Resignation of Tian Huimin as Joint Company Secretary
Abbisko Cayman's Unit Presents Pre-Clinical Study of Liver Cancer Drug at AACR Annual Meeting
Abbisko Cayman Completes Patient Enrollment for Phase 3 Trial of Joint Tumor Treatment
Abbisko Therapeutics Co., Ltd. Completes All Patient Enrollment for the Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib
Abbisko Cayman's Attributable Loss Narrows as Revenue, Other Gains Rise
Abbisko Cayman to Buy Back, Cancel Up to HK$100 Million Shares
Abbisko Cayman Limited commences an Equity Buyback for 70,219,935 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2023.
Abbisko Cayman Limited Reports Earnings Results for the Full Year Ended December 31, 2023
Abbisko Cayman Completes Dosing for Phase 1 Trials for Lung Cancer Treatment
Abbisko Cayman Receives $70 Million Upfront Payment for Licensing of Tumor Treatment
Abbisko Cayman Trustee Buys 6.1 Million Shares Under Restricted Share Scheme
European Medicines Agency Grants Orphan Drug Designation to Abbisko's Tumor Drug
Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib （ABSK021）
Abbisko Cayman Doses First Participant in Phase 1 Trial for Anti-Tumor Treatment; Shares Fall 3%
Abbisko Therapeutics Co., Ltd. Completes the First Patient Dose in the Clinical Trial for Its Next-Generation CD73 Inhibitor ABSK051
Abbisko Cayman Unit Gets US FDA Fast-Track Status for Tenosynovial Giant Cell Tumor Treatment
Abbisko Therapeutics Announces U.S. FDA Grants Fast Track Designation for CSF-1R Inhibitor Pimicotinib
Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck
Abbisko Cayman Doses First Patient in Phase 2 Trial for Pancreatic Cancer Treatment
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3C4Y0 Aktie
  4. Nachrichten Abbisko Cayman Limited
  5. Andere Sprachen